UPDATE | COVID-19 and Vaccination
Kuala Lumpur | The Drug Control Authority (DCA) has granted conditional registration approval for emergency use involving two more COVID-19 vaccines.
The decision, which was finalised at the 361st DCA meeting today, covers the use of Sinopharm and Johnson & Johnson (J&J) vaccines, making them the fifth and sixth type of vaccine included in the National COVID-19 Immunization Program (PICK) portfolio.
Director-General of Health, Tan Sri Dr Noor Hisham Abdullah, announced the matter, said COVILO is a vaccine developed by China National Biotec Group Company Limited (CNBG), Sinopharm, and is known as Sinopharm COVID-19 vaccine.
He said the J&J vaccine, which requires only one injection dose, was developed by Janssen Pharmaceutica N.V. from Belgium.
Comments
Post a Comment